Indacaterol - Novartis

Drug Profile

Indacaterol - Novartis

Alternative Names: Arcapta Neohaler; Hirobriz Breezhaler; Indacaterol maleate; Onbrez Breezhaler; Onbrez Inhalation Capsules; Onbrize Breezhaler; Oslif Breezhaler; QAB 149

Latest Information Update: 28 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Antiasthmatics; Bronchodilators; Indans; Quinolones; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • Phase III Asthma

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 18 Jan 2018 Novartis completes a phase II trial for Asthma in USA (Inhalation) (NCT03257995)
  • 24 Aug 2017 Novartis plans a phase II trial for Asthma in USA(NCT03257995)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top